Coadministration is contraindicated due to the potential for serious and/or life threatening adverse reactions. Based on theoretical considerations darunavir/cobicistat may increase ergotamine exposure.

Co-administration is contraindicated due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Co-administration is expected to increase ergotamine concentrations.